Person-centred pharmaceutical care reduces emergency readmissions

Julia Blagburn,1 Ben Kelly-Fatemi,1 Nasima Akhter,2 Andy Husband3

ABSTRACT
Background Unplanned readmissions to hospital are used in many healthcare systems as a quality indicator of care. Identifying patients at risk of readmission is difficult; existing prediction tools are only moderately sensitive. Correlations exist between certain medicines and emergency readmission, but it is not known whether the association is direct or indirect.

Objectives To determine whether person-centred pharmaceutical care bundles, comprising individualised medicines information, risk management and/or support in taking medicines, might prevent unplanned readmissions by improving adherence and reducing avoidable harm from prescribed medications.

Methods We designed and implemented person-centred pharmaceutical care bundles for patients who were socially isolated and/or on high-risk medicines on one older people’s medical ward for 1 year from February 2013. Another ward with similar patient demographics, service characteristics and a standard clinical pharmacy service was used as a comparator in a prospective cohort study. Readmission rates were retrospectively studied for 12 months before the intervention and during the 12-month intervention period.

Results The readmission rates for the intervention and control wards in the 12 months before the intervention were not significantly different. During the intervention period, the readmission rate was significantly lower on the intervention ward (69/418) than on the control ward (107/490; 17% vs 22%, p=0.05, z=2.05, two-sample z test for difference in proportions of unrelated samples).

Conclusions Person-centred pharmaceutical care bundles were significantly associated with reduced risk of emergency hospital readmission in this study. Further evaluation of the model is warranted.

INTRODUCTION
Unplanned readmission to hospital is used in many healthcare systems as a quality indicator because some will be the result of poor inpatient care or badly organised support or rehabilitation after discharge. The proportion of readmissions that are avoidable is difficult to specify as the criteria outlined in published studies, used to determine whether an admission was avoidable, are often subjective.1

As an incentive to improve inpatient care and discharge process quality, English National Health Service (NHS) acute care hospital Trusts face financial penalties as a consequence of emergency readmissions.2 The UK Department of Health, and thus the definition used in this paper, defines emergency readmissions as unplanned hospital admissions occurring within 30 days of the previous, last hospital discharge, but excluding admissions for malignant cancer, cancer chemotherapy or specialist obstetric or mental health services. Numbers of emergency readmissions are collected routinely in the UK as part of each Trust’s Hospital Episode Statistics, the means by which Trusts are paid for the care they provide. The data are also used at a local and national level for resource management, information and clinical governance.

Clinicians and managers working to reduce readmissions in the UK face a number of challenges. The majority of the published evidence around hospital readmissions comes from health settings in the USA or Canada and may not be directly transferable to the UK.3 4 In addition, identifying patients at risk of readmission is difficult; healthcare and social care professionals are unable to accurately predict which individual patients will be readmitted5 6 and prediction tools for hospital readmission within 30 days have moderate sensitivities at best7 although certain prediction tools may be more discriminatory in particular patient populations. 8 Although multiple hospital admissions are demonstrably associated with future admission,9 modelling with patient-specific factors such as medical conditions rather than epidemiological factors does not appear to increase the sensitivity of readmission prediction tools for medical patients;10 11 this suggests that the health belief model and health behaviours of individuals might be important factors in readmission. A further challenge lies in preventing the readmissions that have been predicted; staff resource is increasingly under pressure in the NHS because of ongoing cost-saving programmes but proven interventions tend to be resource intensive, particularly if conducted in the patient’s home.3

Newcastle upon Tyne Hospitals NHS Foundation Trust (henceforth referred to as the Trust) is an 1800 bed teaching hospital in the North of England. Data from the Office for National Statistics show that our local population has some of the highest deprivation indices and lowest life expectancies in the UK. A 2012 audit of readmissions occurring in 1 week within the Trust identified medicines as a causal/contributing factor in 16 of 81 cases (20%). Twelve of those medication-related readmissions (75%) were judged by a multidisciplinary team to have been avoidable. Weak-to-moderate correlations can be found in the literature between certain medications and likelihood of readmission, namely, corticosteroids, psychoactive agents especially opioids, anti-epileptics, anti-neoplastics, immune-modulating agents, non-steroidal anti-inflammatory agents, anticoagulants, diuretics, drugs acting on the renin–angiotensin–aldosterone system and anti-
diabetic agents including insulin,12–14 but it is not known whether these medicines are causal factors in readmission. The correlation may be an indirect association between those medications and long-term conditions such as heart failure or chronic obstructive pulmonary disease that are known to have high healthcare use and be associated with polypharmacy.

Polypharmacy (defined as five or more prescribed medicines),15 poor discharge planning,16 poor communication with the patient,17 or the primary care team,18 at transfer of care and inadequate follow-up by the hospital19–21 have been found in observational studies to result in adverse patient outcomes including unplanned or avoidable readmission.22 It is therefore plausible that the behaviours of healthcare professionals and/or patient-specific factors such as medical condition(s) and adherence to treatment(s) may be more accurate predictors of hospital readmission risk than the individual’s epidemiological grouping.23 The majority of effective interventions identified from the literature were face-to-face and person-centred; five key themes emerged from our literature review and are shown in figure 1.

Our hypothesis was that person-centred pharmaceutical care during and after a hospital admission, that is meeting each individual’s need for information, risk management or support to take their medicines, may reduce the rate of emergency readmissions caused by non-adherence or troublesome side effects. Traditionally, encounters between clinical pharmacists and patients have been pharmacist led with the goal of giving information. In our new pharmaceutical-care model, the encounters between the clinical pharmacists and patients were conversations led by patients where pharmacists spent more time listening than talking and the goal was to help the patient and carer share treatment decisions and find solutions to any problems identified. In addition, person-centred pharmaceutical care bundles were developed by the clinical pharmacy team for each of the medication types known to be correlated with readmission; two are shown as illustrative examples in figures 2 and 3. Existing national or local procedures for medication risk minimisation, such as National Patient Safety Agency (NPSA) guidance, were built into the care bundles.

Although a large number of person-centred interventions designed to reduce emergency readmissions were identified in the literature, description or evaluation of the intervention was often vague or absent from the original articles. The clinical pharmacy team mapped the risks associated with a medical admission or transfer of care for older people, identified interventions that had demonstrated effectiveness for managing those risks (eg, Teach-back,24 careful medicine reconciliation, shared decision making, motivational interview techniques, real-time discharge communication, assessing a person’s usual support network for suitability, providing person-centred information) and incorporated these into a patient-level document to be used alongside and to record completion of the pharmaceutical care bundles. A standard operating procedure (SOP) was chosen as the mechanism for introducing the care bundles to pharmacy practice because the pharmacy team was already familiar with the benefits of SOP on controlling variation in processes. A detailed description of the intervention, patient assessment tool and pharmaceutical care bundles can be accessed as an online supplementary file.

Hospital pharmacy staff are well placed to identify and address these needs during an admission, but are often not resourced or commissioned to provide domiciliary services after hospital discharge. The New Medicines Service (NMS) and targeted Medicines Use Reviews (MUR) are Community Pharmacy services designed to address a person’s medication-related needs and are UK NHS funded in a broad range of circumstances including recent hospital discharge.25 The opportunity exists for hospital and community pharmacy teams to join-up to provide person-centred pharmaceutical care across the primary–secondary care interface.26

This paper describes the effect of introducing the intervention on an older people’s medical ward in a prospective, cohort study design.

**METHODS**

**Ethical consideration**

This was an observational study that assessed the effectiveness of a service improvement on readmission rather than implementing a new regimen of treatment and therefore full ethical approval was not required for this exercise. The study complies with the relevant principles of good practice in research and data protection.

**The intervention and patient record**

To maximise the chances of successful adoption by the pharmacy team, pharmacy staff working on the intervention ward were engaged as key stakeholders in the design and testing of the person-centred pharmaceutical care bundles, SOP and a patient-level document to record care-bundle completion.27

**Figure 1** Key themes identified as effective components in preventing readmissions. NMS, New Medicines Service; MUR, Medicines Use Reviews.
The patient-level documentation was designed according to the Trust standard format and refined after piloting to make it as quick and easy to complete as possible; a time–motion observation of the pharmacy technician working with five patients suggests that 10 min per patient was required to complete the document.

Each patient admitted to the intervention ward was screened by the pharmacy team as prescribed by the SOP and the pharmacy team implemented any relevant care bundles during the patient’s stay and at discharge. Patients who had a longer stay on the ward were rescreened once a week using the SOP to identify any new medication-related risks or changes to discharge plans. Patients discharged from the intervention ward were offered a referral to their community pharmacy for NMS or MUR if they met the eligibility criteria; patients who met the eligibility criteria, but could not receive the service because they were housebound were offered the same services delivered by the hospital pharmacy team.

**Description of the patients and pharmacy staff on the intervention and control wards**

Two wards specialising in the care of medical patients over 80 years of age with similar service statistics (Healthcare Resource Groups and average length of stay) were identified for the study; one was selected at random to be the intervention ward and patients were consequently allocated non-experimentally to either the intervention or control ward by the hospital bed management team who were unaware that a study was taking place. Both wards already had a named pharmacist for 5 days per week who performed medicines reconciliation after admission, some patient education and clinical medication review. Fifteen hours per week of pharmacy technician time was allocated to the intervention ward to deliver the intervention in conjunction with the pharmacist. To minimise confounding, the pharmacy technician did not work on the control ward and pharmacists working on the control ward were prevented from seeing the person-centred pharmaceutical care bundles or the individual patient checklist.

**Data and variables**

Readmission rates and average length of stay were obtained for each ward from the Trust Informatics Department; these are routinely collected monthly hospital activity data. The data for pharmaceutical care bundle completion rate for the intervention period and the numbers of patients requiring a home visit or telephone call after discharge were retrospectively collected from each patient-level record card. Medicine reconciliation rate was audited biannually for routine performance reports by a pharmacist unrelated to the study. Patient and general practitioner (GP) feedback was captured by self-administered postal questionnaire over 2 months of the intervention period; the questionnaires were deliberately short and contained a first-class stamped, addressed envelope to help secure a good response rate. The data were analysed by a researcher with statistical

**Figure 2** Person-centred pharmaceutical care bundle for opioids.

**Figure 3** Person-centred pharmaceutical care-bundle for corticosteroids. COPD, chronic obstructive pulmonary disease; NMS, New Medicines Service. FRAX is the name of a published tool, the FRAX(R) tool, available at https://www.shef.ac.uk/FRAX/tool.jsp
expertise. As this was a natural experiment without randomisation and with an unknown effect size, formal sample size calculation was not considered. The data obtained from this study will help to power a future trial. A 12-month intervention period was selected to evaluate sustainability of the model and eliminate the possibility of confounding by seasonal variations in readmission rate.

**Analysis**

Using summary data for before and during intervention periods, estimates of risk difference, OR were estimated by a researcher with statistical expertise. Breslow–Day and Tarone’s statistics test was used to test for homogeneity of OR from during and before intervention periods. Fisher’s exact test was used to analyse available data for intervention period to examine whether proportion of readmission varied by the different components of treatment plan. The analysis was done separately for intervention and control ward, as well as for examining overall (combined for both ward) difference in proportion readmitted by the different components. Logistical regression analysis was done to examine whether readmission rate varied significantly between intervention and control wards and also to identify variables that were significantly associated with readmission (control for other variables). IBM SPSS Statistics, V.20 was used to analyse the data. The qualitative data from patient and GP questionnaires are simply described.

**RESULTS**

**Outcome measures**

During the intervention, readmission rate was 5% lower in intervention ward in comparison with that of the control ward (Table 1). The odds of readmission for the control ward was 41% higher than the odds of readmission for the intervention ward during the intervention period (OR=1.41, 95% CI 1.01 to 1.98). However, the control ward had lower odds of readmission than the intervention ward at baseline (OR=0.82, 95% CI 0.56 to 1.14). The Breslow–Day and Tarone’s test examined the homogeneity of OR between the two periods and found that they were significantly different. This qualitative interaction suggests that the intervention may have a positive impact on hospital readmission. Therefore, the subsequent analyses were done for the data obtained during the intervention period only to identify risk factors for hospital readmissions.

Figure 4A shows the variability in monthly readmission rates for the intervention and control wards in the months before the intervention; figure 4B shows the same parameters during the intervention period; the intervention ward has lower readmission rates than the control ward for 10 of the 12 months of the intervention period.

Average length of stay did not change significantly on either ward during the intervention period. Medicines reconciliation after admission was recorded for 100% of patients sampled on both the intervention and control wards in both biannual audit periods.

In the intervention ward, readmission was significantly associated with monitored dosage system (MDS) use (readmission=16.8% and 7.4% among service users vs non-service users, respectively; risk difference=9.4%; p=0.03) and whether the discharge medication list was sent in real time or not (22.7% vs 7.9% among service users and non-service users, respectively; risk difference=14.8%; p<0.001). ORs for these factors are shown in Table 2. However, there was no significant difference in readmission rate for the other treatment components (all p>0.05). Multivariable logistical regression analysis showed that controlling for other factors (MDS use, requirements of self-medication assessment, sending discharge medicine in real time), the likelihood of patients being readmitted was less where pharmacy staff completed actions prescribed by the SOP compared with patients who were discharged before the prescribed actions were completed (OR=0.339, 95% CI 0.299 to 0.969; p=0.039).

An average of three patients per month required follow-up after discharge by the hospital pharmacy team. Ninety per cent of follow-up was possible by telephone and the telephone calls were signiﬁcantly more likely to be associated with reduced readmissions than the control ward (Table 3). The analysis was done separately for intervention and control wards and also to identify variables that were signiﬁcantly associated with readmission (control for other variables). IBM SPSS Statistics, V.20 was used to analyse the data. The qualitative data from patient and GP questionnaires are simply described.

**Table 1** Readmissions within 30 days for the intervention and control wards before and during the intervention

<table>
<thead>
<tr>
<th>Patient numbers</th>
<th>Control ward</th>
<th>Intervention ward</th>
<th>Two sample z-test for difference in population proportions</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Discharges</td>
<td>Readmissions</td>
<td>Discharges</td>
</tr>
<tr>
<td>12-month period prior to intervention</td>
<td>446</td>
<td>72 (16.1%)</td>
<td>403</td>
</tr>
<tr>
<td>12-month intervention period</td>
<td>490</td>
<td>107 (21.8%)</td>
<td>418</td>
</tr>
<tr>
<td>Pearson’s goodness-of-fit χ² test for difference in proportions</td>
<td>χ²=3.33, p=0.068</td>
<td>χ²=1.52, p=0.375</td>
<td></td>
</tr>
</tbody>
</table>

Figure 4 readmission rate (%) for the intervention and control wards before (A) and during (B) the intervention.
The prolonged period where the readmission rate for the intervention ward was lower than control ward (figure 4B) is unusual behaviour for readmission rates and suggests that the intervention was having an effect. Interestingly, the magnitude of the observed difference is similar to that observed in Leeds Teaching Hospitals IMPACT study where hospital pharmacy joined up with community pharmacy at transition of care in a similar patient group.29

The association between MDS use and increased risk of readmission observed in our study is interesting and warrants further investigation. The association may be the indirect result of the characteristics of patients who are provided with MDS (often people vulnerable to adverse drug events because of polypharmacy or cognitive impairment) or the direct result of MDS removing a link between patients and their medicines. The association we observed between real-time discharge communication and increased risk of readmission is possibly also a reflection of the impact of MDS use; the intervention SOP directed pharmacy staff to real-time discharge communication for patients with MDS and/or district nurse support with insulin to reduce dosing errors as a result of changes made in hospital.

The wards chosen for this study are typical of acute medical wards for older people in UK teaching hospitals but our results may not be transferable outside this specialty.

### DISCUSSION

Our results suggest that the risk of medication-related readmissions can be reduced with person-centred pharmaceutical care and that pharmaceutical care bundles are a practicable way to introduce person-centred care with medicines to an acute teaching hospital in the UK NHS.

Our study has several limitations relating to the design and conduct. For pragmatic reasons, our primary outcome measure was obtained from clinical coding data, which is known to contain inaccuracies; a recent audit conducted on behalf of the UK Department of Health identified wide inter-Trust coding error variation with an average error rate of 7%.29 Patients were not involved in the design of the study and their perspectives may have caused us to alter the design or delivery of the intervention. As a cohort study, there may be factors influencing readmission rate that we cannot measure or control. For example, the two wards in our study have different lead clinicians; those clinicians may impact the culture of the ward and subsequently on discharge planning and readmissions, but that effect would be difficult to quantify objectively. Loss to follow-up can be a difficulty in cohort studies, but was not a major issue in this study. We hypothesise that this is the result of the need for planned discharge in this patient group, which typically occurs within usual working hours because support services are often unavailable outside those hours. Only one patient was transferred from the intervention to the control ward in the 12-month intervention period, those data have not been excluded from our results, but are unlikely to have an effect on our primary outcome measure. We did not examine the sociodemographic or socioeconomic characteristics of patients on the intervention or control wards; although there is no reason to expect a difference, this potentially confounds our results.

The apparent reduction of readmission rate in our study should be received cautiously for the reasons described above and because the study was not powered to detect this difference.

### Table 2 Multivariate logistical regression analysis examining factors associated with readmission

<table>
<thead>
<tr>
<th>Indicators</th>
<th>OR</th>
<th>95% CI Lower</th>
<th>95% CI Upper</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intervention effect (ward)</td>
<td>0.539</td>
<td>0.299</td>
<td>0.969</td>
</tr>
<tr>
<td>Uses MDS</td>
<td>1.619</td>
<td>0.903</td>
<td>2.905</td>
</tr>
<tr>
<td>Self-medication assessment required</td>
<td>0.494</td>
<td>0.271</td>
<td>0.898</td>
</tr>
<tr>
<td>Discharge medication list sent in real time</td>
<td>2.423</td>
<td>1.359</td>
<td>4.322</td>
</tr>
<tr>
<td>Constant</td>
<td>0.166</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

MDS, monitored dosage system.

**Key messages**

- Readmission risk prediction models are widely used but not sensitive.
- A number of medications are correlated with readmission but a causal link is not established.
- Person-centred risk assessment and risk management for older people and their medications in hospital may reduce the likelihood of 30-day readmission by 40%.
- Using a monitored dosage system for medicines at home may be a significant risk factor for hospital readmission.

**Twitter** Follow Julia Blagburn at @juliablagburn

**Acknowledgements** Karen Glasper and Christine Baty, Pharmacy Technicians at Newcastle upon Tyne Hospitals NHS Foundation Trust. David Grainger, General Practitioner, Newcastle West Clinical Commissioning Group. Adetayo Kasim, Research Statistician, Wolfson Research Institute for Health and Wellbeing, for providing support with statistical analysis.

**Contributors** Planning of the study including literature search and design of the intervention and data collection tools was done by JB and BK-F. The study was conducted by JB and KG. Statistical design and analysis was done by NA and AK. JB drafted the article which was revised by AH, BK-F, DG and AK.

**Funding** Newcastle West Clinical Commissioning Group supported this study by funding a Pharmacy Technician for 15 h per week for 1 year.

**Competing interests** None declared.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** Anonymised data are available on request from the corresponding author.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Eur J Hosp Pharm: first published as 10.1136/ejhpharm-2015-000736 on 1 October 2015. Downloaded from http://ejhp.bmj.com/ on June 14, 2021 by guest. Protected by copyright.
REFERENCES
2 Department of Health Payment by Results team (2012). A simple guide to Payment by Results. London: Department of Health, Gateway reference 18135.
6 O’Toole R, Campbell PMF. Predicting readmissions of patients from an elderly care ward. Age Ageing 2012;41:0002–729.
Medicine Reconciliation
Clinical medication review
Ad hoc patient education
Patient discharge
Doctor prepares discharge letter

Ward clerk sends discharge letter to GP
Named nurse communicates with district nurse

Control Ward

Patient Admission
Medicine Reconciliation
Clinical medication review
Ad hoc patient education
Patient discharge
Doctor prepares discharge letter

Ward clerk sends discharge letter to GP
Named nurse communicates with district nurse

Intervention Ward

Patient Admission
Medicine Reconciliation
Medicines support needs assessed

Unmet needs identified?
Yes
Agree actions with patient

Clinical medication review and action pharmaceutical care bundles
Discussion with patient or carer about medication changes and education if needed

Patient Discharge
Doctor and pharmacist prepare discharge letter

Hospital pharmacist communicates with others (e.g. community pharmacist, home carers, care home) as needed

Hospital pharmacy staff deliver NMS or MUR if patient is eligible but community pharmacist cannot deliver
Medicines Support Needs Assessment

This form is to be used to assess the support required by a patient to aid medication adherence. It can also be used to determine if a reasonable adjustment is required from the pharmacist or prescriber under the Disability Discrimination Act (1995). The assessor will need to make a professional judgment on the type(s) of support needed after discussion with the patient to ensure the patient derives maximum benefit from their medication in line with their preferences and values.

File in discharge planning section of nursing notes once complete.

Brief adherence and concordance assessment tool (BACAT)

Introduction: these questions are to help us find out whether you need more information or support with your medicines.

Use non-judgmental tone and language

1. Do you have difficulty getting the medicines from the doctor or pharmacy?  
   Yes No

2. Do you have difficulty in opening the packets …, swallowing the tablets … or using the cream… or eye drops…?  
   Yes No

3. Do you have difficulty reading the labels and instructions on your medicine packets?  
   Yes No

4. Do you think you have missed or forgotten any doses in the week before you came into hospital?  
   Yes No

5. Have you needed to take any extra doses of your medicines - more than your doctor prescribed?  
   Yes No

6. Do you have any concerns about your medicines? Do your medicines give you side effects or upset you?  
   Yes No

7. Could your medicines work better? Do you think you need something else?  
   Yes No

Completed by (name) .................................................... (signature) .............................................. (date) ..................

If patient answered yes to any question refer them to your clinical pharmacist. Referral made? Yes / No Date ..................

Comprehensive assessment

(to be completed by a clinical pharmacist when problems are identified by using the screening tool above)

Current support (availability, limitations etc.)

Family / friend | District nurse | Home care | Other

Complexity of current regimen

<table>
<thead>
<tr>
<th>Morning</th>
<th>Midday</th>
<th>Evening</th>
<th>Night</th>
<th>No. prn meds</th>
<th>Any non-standard dose times?</th>
<th>Variable doses?</th>
</tr>
</thead>
</table>

Notes: Review medicines (any recognised criteria for medication review may be used e.g. STOPP/START, Strand or MAI) and discuss potential and actual problems with patient and prescriber. The regime should be designed around the patient’s lifestyle and preferences, not just simplified by the pharmacist.
<table>
<thead>
<tr>
<th>Problem or concern identified</th>
<th>Potential forms of support</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eyesight</td>
<td><strong>Brand recognition</strong>: where patients rely on distinctive packaging livery, document as a need on drug chart and in electronic clinical notes.</td>
</tr>
<tr>
<td></td>
<td><strong>Large print labels</strong>: suitable if can read larger script, e.g. 20 point:</td>
</tr>
<tr>
<td></td>
<td><strong>Take TWO tablets THREE times daily</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Talking labels</strong>: Reusable. One off initial cost covered by hospital, but there is a need to consider who will transfer the labels to new medicine boxes each month (carer, community pharmacy, family)</td>
</tr>
<tr>
<td></td>
<td><strong>Dexterity / swallowing</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Specifically for eye drops</strong></td>
</tr>
<tr>
<td></td>
<td>Ability to accurately get the drop into the eye</td>
</tr>
<tr>
<td></td>
<td>Ability to squeeze the bottle to deliver the drop</td>
</tr>
<tr>
<td></td>
<td><strong>Consider alternative</strong>: medicine, dosage form, inhaler device, Haleraid® etc.</td>
</tr>
<tr>
<td></td>
<td><strong>New technique</strong>: fingernail/teaspoon to open blister pack, double sip or Pill-glide® to aid swallowing, assess inhaler technique.</td>
</tr>
<tr>
<td></td>
<td><strong>Consider eye drop delivery devices</strong> e.g. Opticare®, and Opticare Arthro®. Document brand name of the device.</td>
</tr>
<tr>
<td></td>
<td><strong>Understanding</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Specifically for eye drops</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Understanding</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Access</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Concerns about medicines or informed decision NOT to take medicines</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Other identified issue</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Notes + Actions agreed with patient / carer to reduce the limitations to adherence:</strong></td>
</tr>
</tbody>
</table>

**Notes**

Consider if there any potentially reversible causes of confusion or poor memory present. For example, history of alcohol use, signs of acute infection, drug therapy, hyponatraemia or recent head trauma.

Any deficiency in performance on Mini-COG test indicates that a person is not competent to fill their own medibox. Be aware that this person may also not be able to give informed consent e.g. for services.

Refer to community pharmacist for NMS/MUR if patient has new medicine(s) or any ongoing need for support.
# REACH: Pharmaceutical Care Bundles

*Medicines linked with hospital admission & readmission*

<table>
<thead>
<tr>
<th>High Risk Medicine Group</th>
<th>Pharmaceutical Care Bundle</th>
</tr>
</thead>
</table>
| **ANTICOAGULANTS**
*Tinzaparin*
[NPSA - Reducing treatment dose errors with low molecular weight heparins (LMWH) (Rapid Response Report, July 2010)] | • Check indication, patient weight and renal function for patients provided treatment doses of LMWH.
• If for discharge:
  o Check patient/carer can self-administer (including how to give a part syringe without removing air bubble) or district nurse (DN) has been informed.
  o Check that duration of therapy after discharge & supply is appropriate and understood by patient/carer/DN. |
| **ANTICOAGULANTS**
*Warfarin & Coumarins*
[NPSA - Actions that can make anticoagulant therapy safer (Patient Safety Alert, March 2007)] | • Ensure inpatient is managed appropriately using Trust guideline.
• If new prescription for an indication where NOACs are licensed, check patient was involved in choice of anticoagulant using patient decision aids at www.patient.co.uk.
• Complete the Trust inpatient anticoagulation counseling checklist with the patient and file in medical notes.
• Ensure patient knows dose on discharge and when to expect/attend for monitoring.
• Ensure appropriate follow up has been arranged post discharge.
• Physically check yellow book completed before patient leaves hospital and that patient knows to carry alert card on their person.
• DATIX report any poorly prescribed or inappropriately omitted doses. |
| **ANTICOAGULANTS**
*Non-vitamin K Oral Anticoagulants (NOACs)* | • Check dose is appropriate for age and renal function.
• If new prescription for an indication where NOACs are licensed, check patient was involved in choice of anticoagulant using patient decision aids at www.patient.co.uk.
• Check patient aware of danger signs (bleeding), and what to do.
• Complete the Trust inpatient anticoagulation counseling checklist with the patient and file in medical notes.
• Give patient a NOAC alert card (generic or from manufacturer) to carry on their person. |
| **HYPOGLYCAEMIC AGENTS**
*Insulin*
[NPSA Safer administration of insulin (Rapid Response Report, June 2010)] | • Clinical medication review must include review of blood glucose results.
• Review and complete insulin passport if patient chooses to carry one.
• Provide information from/signpost to ‘NHS and Diabetes’ at www.diabetes.co.uk/nhs.
• DATIX report any poorly prescribed or inappropriately omitted doses. |
| **Oral hypoglycaemic agents** | - Check patient knows the signs and symptoms of hypoglycaemia, and has a reasonable plan of action if they feel a ‘hypo’ coming on.  
- Provide information from/ signpost to ‘NHS and Diabetes’ at www.diabetes.co.uk/nhs. |
| **ANTIMICROBIALS** | - Ensure choice and dose appropriate with regard to indication/GFR/sensitivities – guideline/microbiologist advice.  
- Ensure that indication stated is correct and current.  
- Ensure course length/review date is clearly stated and appropriate.  
- If necessary, ensure TDM is carried out at appropriate points throughout the course, and instructions for further monitoring are communicated on discharge. See Trust Pharmacy TDM guidelines for more information.  
- Suspend proton pump inhibitor (PPI) unless benefits outweigh risk. See Trust PPI prescribing guideline for more information.  
- Ensure patient is aware at discharge of duration, need to complete course and any drug-specific points e.g. diarrhoea with clindamycin, food/drug interactions with linezolid. |
| **CORTICOSTEROIDS Inhaled** | - Check & give advice on patient’s use of inhalers/nebuliser using Teach-Back® technique.  
- **COPD** – Consider rescue packs of steroid/antibiotic for home if appropriate and acceptable to patient and prescriber. |
| **CORTICOSTEROIDS Oral** | - Ensure patient-held records are completed/up to date.  
- Talk with patient about use, benefits, side effects and ‘danger’ symptoms. Consider using NMS template for discussion.  
- FRAX assessment if patient falls/is at risk of falls and consider fracture prophylaxis if appropriate and acceptable to patient and prescriber.  
- If prescribed PPI, risk vs benefit discussion with patient and prescriber. |
| **ANTIEPILEPTIC MEDICATIONS** | - If therapeutic drug monitoring is necessary, advise non-specialist prescribers about dose changes and monitoring interval if levels are not within desired range.  
- Monitor patient closely whilst unwell for deterioration in renal function, serum sodium level and drug interactions.  
- Confirm and annotate drug chart with drug brand name.  
- Communicate serum levels, how drug interactions have been managed and monitoring recommendations to GP on discharge prescription. |
| **ANTIPSYCHOTICS** | - Ensure specific indication is documented on prescription.  
- If short term prescription (e.g. delirium):  
  - Ensure ongoing need is reviewed weekly using Trust antipsychotic review guideline.  
  - Consider giving the patient a knitted comforter.  
  - Make patient decision aid from patient.co.uk available to next of kin so they can be involved in decision to use drug therapy.  
- If needed at or after discharge, ensure specific indication and |
| LITHIUM | 
|---|---|
| [NPSA - Safer lithium therapy (Patient Safety Alert, December 2009) and Trust Pharmacy TDM guidelines] | 
| - Ensure serum level has been requested unless checked and satisfactory within last three months.  
- Confirm and annotate drug chart with lithium brand.  
- Monitor patient closely whilst unwell for deterioration in renal function, serum sodium level and drug interactions.  
- Talk with patient about factors influencing adherence unless that was done earlier as part of Medicines Support Needs Assessment.  
- Check that medication regimen fits patient’s lifestyle, values and preferences. Discuss any problems identified with the patient’s mental health professional.  
- Complete a medication reminder card with the patient, using their preferred terminology. |

| ANTIDEPRESSANTS | 
|---|---|
| | 
| Talk with patient about factors influencing adherence unless that was done earlier as part of Medicines Support Needs Assessment.  
- Check that medication regimen fits patient’s lifestyle, values and preferences. Discuss any problems identified with the patient’s mental health professional.  
- Complete a medication reminder card with the patient, using their preferred terminology. |

| OPIOIDS | 
|---|---|
| - Prioritise medicine reconciliation for patients prescribed strong opioids, following Trust procedure.  
  - Confirm any recent opioid dose, formulation, frequency of administration and any other analgesic medicines prescribed for the patient with two sources, the patient being one source wherever possible.  
- Check the usual starting dose, frequency of administration, standard dosing increments, symptoms of overdose, and common side effects of that medicine and formulation.  
- Ensure where a dose increase is intended, that the calculated dose is safe for the patient.  
  - Ensure dose increase is not more than 50% higher than previous dose.  
  - Clinical medication review must be carried out at every dose increase including a discussion with patient about their pain control, pain management preferences and side effects. |